{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cleveland&page=35&state=Ohio",
    "query": {
      "state": "Ohio",
      "city": "Cleveland",
      "page": 35
    },
    "page_size": 10
  },
  "pagination": {
    "page": 35,
    "page_size": 10,
    "total_count": 11335,
    "total_pages": 1134,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cleveland&page=36&state=Ohio&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cleveland&page=34&state=Ohio&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-08T02:44:06.206Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01498289",
      "title": "S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Gastroesophageal Junction",
        "Esophageal Cancer",
        "Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "FOLFOX regimen",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 213,
      "start_date": "2012-02",
      "completion_date": "2019-09-19",
      "has_results": true,
      "last_update_posted_date": "2019-11-07",
      "last_synced_at": "2026-11-08T02:44:06.206Z",
      "location_count": 508,
      "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Auburn, California + 320 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Burlingame",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01498289"
    },
    {
      "nct_id": "NCT02528253",
      "title": "A Phase 3 Study of Tanezumab for Chronic Low Back Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Low Back Pain"
      ],
      "interventions": [
        {
          "name": "Placebo to Week 16; tanezumab 5mg SC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to Week 16, tanezumab 10 mg SC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tanezumab 5 mg SC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tanezumab 10 mg SC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tramadol PR oral",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1832,
      "start_date": "2015-08-18",
      "completion_date": "2018-12-20",
      "has_results": true,
      "last_update_posted_date": "2020-02-21",
      "last_synced_at": "2026-11-08T02:44:06.206Z",
      "location_count": 179,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Saraland, Alabama + 124 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02528253"
    },
    {
      "nct_id": "NCT07567001",
      "title": "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obesity",
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "NNC0487-0111",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5610,
      "start_date": "2026-05-11",
      "completion_date": "2029-08-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-11-08T02:44:06.206Z",
      "location_count": 206,
      "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 173 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07567001"
    },
    {
      "nct_id": "NCT07490301",
      "title": "A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Pancreatic Ductal Adenocarcinoma",
        "PDAC"
      ],
      "interventions": [
        {
          "name": "Telisotuzumab adizutecan",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Folinic acid/ Leucovorina",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 900,
      "start_date": "2026-04-30",
      "completion_date": "2031-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-08T02:44:06.206Z",
      "location_count": 9,
      "location_summary": "New Haven, Connecticut • Chicago, Illinois • Zion, Illinois + 6 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Zion",
          "state": "Illinois"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07490301"
    },
    {
      "nct_id": "NCT01294228",
      "title": "Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Abbott RDx Cardiometabolic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 1001,
      "start_date": "2011-03",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2017-02-02",
      "last_synced_at": "2026-11-08T02:44:06.206Z",
      "location_count": 25,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 21 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01294228"
    },
    {
      "nct_id": "NCT04401865",
      "title": "Safety and Effectiveness of the PXL-Platinum 330 System",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Corneal Ectasia",
        "Keratoconus",
        "Pellucid Marginal Corneal Degeneration"
      ],
      "interventions": [
        {
          "name": "PXL-330 Platinum device for crosslinking with Peschke riboflavin solution",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Colorado Eye Consultants/Cornea Consultants of Colorado",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2020-06-01",
      "completion_date": "2023-06-30",
      "has_results": false,
      "last_update_posted_date": "2022-01-25",
      "last_synced_at": "2026-11-08T02:44:06.206Z",
      "location_count": 3,
      "location_summary": "Littleton, Colorado • Highland Park, Illinois • Brecksville, Ohio",
      "locations": [
        {
          "city": "Littleton",
          "state": "Colorado"
        },
        {
          "city": "Highland Park",
          "state": "Illinois"
        },
        {
          "city": "Brecksville",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04401865"
    },
    {
      "nct_id": "NCT02690207",
      "title": "Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Herpes Zoster"
      ],
      "interventions": [
        {
          "name": "Herpes Zoster Vaccine GSK1437173A",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 8687,
      "start_date": "2016-03-16",
      "completion_date": "2019-03-15",
      "has_results": true,
      "last_update_posted_date": "2021-03-04",
      "last_synced_at": "2026-11-08T02:44:06.206Z",
      "location_count": 37,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02690207"
    },
    {
      "nct_id": "NCT00014144",
      "title": "S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Urethral Cancer"
      ],
      "interventions": [
        {
          "name": "gefitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 31,
      "start_date": "2001-02",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2012-10-08",
      "last_synced_at": "2026-11-08T02:44:06.206Z",
      "location_count": 95,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00014144"
    },
    {
      "nct_id": "NCT00241501",
      "title": "Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastroesophageal Reflux Disease (GERD)"
      ],
      "interventions": [
        {
          "name": "Esomeprazole (Nexium)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 140,
      "start_date": "2004-02",
      "completion_date": "2005-04",
      "has_results": false,
      "last_update_posted_date": "2010-11-19",
      "last_synced_at": "2026-11-08T02:44:06.206Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Wilmington, Delaware + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00241501"
    },
    {
      "nct_id": "NCT03213457",
      "title": "A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Estradiol/Norethindrone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Elagolix",
          "type": "DRUG"
        },
        {
          "name": "Elagolix",
          "type": "DRUG"
        },
        {
          "name": "Placebo for E2/NETA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 681,
      "start_date": "2017-07-07",
      "completion_date": "2023-12-06",
      "has_results": true,
      "last_update_posted_date": "2024-12-20",
      "last_synced_at": "2026-11-08T02:44:06.206Z",
      "location_count": 188,
      "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 140 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03213457"
    }
  ]
}